Economy · World
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Pharmaceutical company Eli Lilly has announced an agreement to acquire Merida Biosciences. The deal is valued at up to $2.875 billion. This acquisition is part of Eli Lilly's strategy to expand its presence in the autoimmune drug market. Merida Biosciences is known for its work in developing treatments for autoimmune diseases.
How outlets across the spectrum covered it
L 0 C 8 R 0
- Centre (8): Australian Financial Review, Bloomberg, CNBC, Mint, Reuters, The Economic Times, The Globe and Mail, The Wall Street Journal